These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 25692292)

  • 1. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer.
    Lucas T; Benihoud K; Vigant F; Schmidt CQ; Wortmann A; Bachem MG; Simmet T; Kochanek S
    PLoS One; 2015; 10(2):e0117254. PubMed ID: 25692292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genetic fiber modification to achieve matrix-metalloprotease-activated infectivity of oncolytic adenovirus.
    José A; Rovira-Rigau M; Luna J; Giménez-Alejandre M; Vaquero E; García de la Torre B; Andreu D; Alemany R; Fillat C
    J Control Release; 2014 Oct; 192():148-56. PubMed ID: 25037019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.
    Shashkova EV; May SM; Doronin K; Barry MA
    Mol Ther; 2009 Dec; 17(12):2121-30. PubMed ID: 19755961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.
    Coughlan L; Vallath S; Gros A; Giménez-Alejandre M; Van Rooijen N; Thomas GJ; Baker AH; Cascalló M; Alemany R; Hart IR
    Hum Gene Ther; 2012 Sep; 23(9):960-79. PubMed ID: 22708837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
    Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
    Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation.
    Schoggins JW; Nociari M; Philpott N; Falck-Pedersen E
    J Virol; 2005 Sep; 79(18):11627-37. PubMed ID: 16140740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.
    Nishimoto T; Yoshida K; Miura Y; Kobayashi A; Hara H; Ohnami S; Kurisu K; Yoshida T; Aoki K
    Gene Ther; 2009 May; 16(5):669-80. PubMed ID: 19225547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model.
    Hu Z; Zhang Z; Guise T; Seth P
    Hum Gene Ther; 2010 Nov; 21(11):1623-9. PubMed ID: 20712434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects.
    Mei S; Peng S; Vong EG; Zhan J
    Int Immunopharmacol; 2024 Aug; 137():112393. PubMed ID: 38852522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues.
    Yamamoto Y; Hiraoka N; Goto N; Rin Y; Miura K; Narumi K; Uchida H; Tagawa M; Aoki K
    J Control Release; 2014 Oct; 192():284-93. PubMed ID: 25108153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strong antitumor efficacy of a pancreatic tumor-targeting oncolytic adenovirus for neuroendocrine tumors.
    Yamamoto Y; Nagasato M; Rin Y; Henmi M; Ino Y; Yachida S; Ohki R; Hiraoka N; Tagawa M; Aoki K
    Cancer Med; 2017 Oct; 6(10):2385-2397. PubMed ID: 28941156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells.
    Prill JM; Espenlaub S; Samen U; Engler T; Schmidt E; Vetrini F; Rosewell A; Grove N; Palmer D; Ng P; Kochanek S; Kreppel F
    Mol Ther; 2011 Jan; 19(1):83-92. PubMed ID: 20959811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species D Adenoviruses as Oncolytic Viral Vectors.
    Bullard BL; Corder BN; Weaver EA
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33291224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver.
    Vigant F; Descamps D; Jullienne B; Esselin S; Connault E; Opolon P; Tordjmann T; Vigne E; Perricaudet M; Benihoud K
    Mol Ther; 2008 Aug; 16(8):1474-80. PubMed ID: 18560416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of viral thymidine kinase gene expression by replicating oncolytic adenovirus and prediction of therapeutic efficacy.
    Kim EJ; Yoo JY; Choi YH; Ahn KJ; Lee JD; Yun CO; Yun M
    Yonsei Med J; 2008 Oct; 49(5):811-8. PubMed ID: 18972602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
    Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
    Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host.
    Zhang Z; Hu Z; Gupta J; Krimmel JD; Gerseny HM; Berg AF; Robbins JS; Du H; Prabhakar B; Seth P
    Cancer Gene Ther; 2012 Sep; 19(9):630-6. PubMed ID: 22744210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in oncolytic adenovirus therapies for cancer.
    Rosewell Shaw A; Suzuki M
    Curr Opin Virol; 2016 Dec; 21():9-15. PubMed ID: 27379906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ad5
    Uusi-Kerttula H; Davies JA; Thompson JM; Wongthida P; Evgin L; Shim KG; Bradshaw A; Baker AT; Rizkallah PJ; Jones R; Hanna L; Hudson E; Vile RG; Chester JD; Parker AL
    Clin Cancer Res; 2018 Sep; 24(17):4215-4224. PubMed ID: 29798908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.